DSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025 Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high…
Reach Resources Limited (ASX: RR1 & RR1O) (“Reach” or “the Company”) is pleased to announce the completion of a…
Rua Gold Inc. (TSXV: RUA) (OTCQB: NZAUF) (WKN: A4010V) (‘Rua Gold’ or the ‘Company’) is pleased to announce the…
triumph gold Corp. (TSXV: TIG) (OTC Pink: TIGCF) (FSE: 8N6) (‘triumph gold’ or the ‘Company’) is pleased to announce…
C29 Metals (C29:AU) has announced Multiple New Multi-Commodity Targets Download the PDF here. This post appeared first on investingnews.com
Radiopharm Theranostics (RAD:AU) has announced Acceleration of RAD204 Phase 1 dose escalation trial Download the PDF here. This post…
Nordic Resources (NNL:AU) has announced Excellent Gold Intersections Verified at Kiimala Project Download the PDF here. This post appeared…
finlay minerals ltd. (TSXV: FYL) (OTCQB: FYMNF) (‘Finlay’ or the ‘Company’) is pleased to announce that it has appointed…
Coverage area includes recently announced gold till anomaly plus two more historic gold occurrences on Matagami property largely subject…